Leerink Partnrs Has Positive Outlook of ENTA FY2025 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Leerink Partnrs lifted their FY2025 earnings per share estimates for shares of Enanta Pharmaceuticals in a report issued on Monday, December 9th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will post earnings per share of ($4.70) for the year, up from their previous forecast of ($4.95). The consensus estimate for Enanta Pharmaceuticals' current full-year earnings is ($4.81) per share. Leerink Partnrs also issued estimates for Enanta Pharmaceuticals' FY2026 earnings at ($2.95) EPS and FY2027 earnings at ($1.70) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The firm had revenue of $14.60 million for the quarter, compared to analysts' expectations of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company's revenue for the quarter was down 22.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.33) earnings per share.

A number of other research analysts also recently issued reports on ENTA. Robert W. Baird cut their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating on the stock in a report on Tuesday, November 26th. HC Wainwright reiterated a "buy" rating and issued a $27.00 price target on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $19.50.

Enanta Pharmaceuticals Stock Performance

ENTA traded down $0.71 during trading on Thursday, hitting $6.29. 780,585 shares of the stock were exchanged, compared to its average volume of 215,225. The firm has a 50 day simple moving average of $10.43 and a 200 day simple moving average of $12.00. The firm has a market cap of $133.31 million, a price-to-earnings ratio of -1.22 and a beta of 0.49. Enanta Pharmaceuticals has a 1 year low of $6.25 and a 1 year high of $17.80.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ENTA. Krensavage Asset Management LLC boosted its position in shares of Enanta Pharmaceuticals by 19.7% in the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company's stock worth $15,520,000 after purchasing an additional 246,736 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in Enanta Pharmaceuticals during the 3rd quarter worth about $1,243,000. Point72 Asset Management L.P. acquired a new stake in Enanta Pharmaceuticals during the 3rd quarter worth about $903,000. Wellington Management Group LLP acquired a new stake in Enanta Pharmaceuticals during the 3rd quarter worth about $360,000. Finally, State Street Corp lifted its position in Enanta Pharmaceuticals by 6.4% during the 3rd quarter. State Street Corp now owns 449,975 shares of the biotechnology company's stock worth $4,662,000 after acquiring an additional 27,147 shares during the period. Institutional investors and hedge funds own 94.99% of the company's stock.

Insider Transactions at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of the firm's stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now owns 801,638 shares of the company's stock, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 13.64% of the company's stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.